Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anakinra + methotrexate
- Development stage
- Unknown
- Lead developer
- Sobi
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Oral
01
Overview
A combination therapy consisting of anakinra (a recombinant form of the endogenous interleukin-1 receptor antagonist) and methotrexate (a disease-modifying antirheumatic drug). This combination is primarily used for treating rheumatoid arthritis that has not responded adequately to methotrexate alone. The combination provides significantly greater clinical benefit than methotrexate monotherapy in reducing the severity of signs and symptoms of rheumatoid arthritis, improving physical function, and decreasing acute phase reactants.
02
Targets
DHFR (Dihydrofolate reductase)IL1R1 (Interleukin-1 Receptor Type 1)IL-1R (Interleukin-1 receptor type 1 (IL-1R1))
Beyond the preview
Go deeper on anakinra + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anakinra + methotrexate.